Literature DB >> 28091502

[Combined therapy of cerebrovascular disorders with neuroprotectors].

M V Putilina1.   

Abstract

Safety of drugs is one of the priorities of modern medicine. The goal of pharmacological treatment is a search for effective and safety drugs as well as a study of possibilities of combined using of the drugs with opposite effects. Basing on the possible therapeutic interactions, 2-ethyl-6-methyl-3-hydroxypyridine succinate can be recommended as a basic medication for patients with cerebrovascular diseases to normalize the energy metabolism of brain cells. The complex use of cholinergic drugs with different neuroprotective effects is effective from the first hours after admission. Cholinergic drugs (citicoline or choline alfoscerate) as the drugs of the first choice should be justified taking into consideration dysfunction of the brain system activation. Patient's age, the level of consciousness, somatic pathology, previous strokes, cognitive impairment are predictors of treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28091502     DOI: 10.17116/jnevro201611611158-63

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  2 in total

1.  Direct and Indirect Neurological Signs of COVID-19.

Authors:  O A Gromova; I Yu Torshin; V A Semenov; M V Putilina; A G Chuchalin
Journal:  Neurosci Behav Physiol       Date:  2021-11-04

2.  SARS-CoV-2 (COVID-19) as a Predictor of Neuroinflammation and Neurodegeneration: Potential Treatment Strategies.

Authors:  M V Putilina; D V Grishin
Journal:  Neurosci Behav Physiol       Date:  2021-06-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.